Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 39

Why Your Lifespan Could Be Thousands of Years — New DNA Research Explained

Can humans live for thousands of years? New DNA and longevity research suggests that aging may not be fixed—it may simply be the result of imperfect cellular repair. In this video, we explore how DNA damage, genetic repair mechanisms, and modern longevity science are reshaping our understanding of human lifespan.

This content is based on current research from USA and Europe, focusing on emerging breakthroughs in genetics, DNA repair therapies, and anti-aging science.
If you’re interested in health, biology, or the future of human longevity, this video is for you.

Disclaimer:
This video is for educational purposes only, is not intended to diagnose, treat, or cure any condition, and does not replace professional medical advice. Always consult a qualified healthcare provider for guidance related to your health.

#LongevityScience.
#DNARepair.
#AntiAging.
#GeneticsResearch.
#HealthFacts.
#BioLogicHealth.
#ScienceExplained.
#HealthyAging

Oral Medications for Treating Agitation in a Safety Net Emergency Department

In this quality improvement study, emergency physicians successfully adopted oral medications for treating agitation, primarily from intoxication.

Question Can emergency physicians adopt using oral medications as first-line treatment for agitation primarily from intoxication?

Findings In this quality improvement study evaluating 460 600 ED encounters, the proportion of patients receiving their first sedating medication orally increased from 7% to 31% after 1 year of the intervention, while time to adequate sedation and adverse events, measured prospectively during implementation, were not different between oral and intramuscular routes.

Use of Flexion-Extension MRI to Reveal Occult Spondylotic Compression in Undifferentiated Cervical Myelopathies With Cord T2 Hyperintensity

Background and ObjectivesIn cervical spondylotic myelopathy (CSM), compression may not be evident in the neutral position, potentially leading to misdiagnosis and delayed treatment. We sought to assess the utility of flexion-extension MRI in revealing…

2025 FDA approvals

Lots of interesting information! The Zevaskyn (“a first cell-sheet-based gene therapy”) approval for treating epidermolysis bullosa (EB) is particularly uplifting. Back in high school, I knew someone with EB. It is a devastating disease. On the less happy side, an AAV9 therapy and an oncolytic virus therapy were rejected this year. [ https://www.nature.com/articles/d41573-026-00001-z](https://www.nature.com/articles/d41573-026-00001-z)

The US FDA approved 46 new drugs in 2025, despite a tumultuous year at the regulatory agency.

Antibody Therapy Eradicates Traces of Multiple Myeloma in Preliminary Trial

Treatment with an immune and cancer cell-targeting antibody therapy eradicates residual traces of the blood cell cancer multiple myeloma, according to interim results from a clinical trial conducted by researchers at Sylvester Comprehensive Cancer Center, part of University of Miami Miller School of Medicine.

None of the 18 patients who completed up to six cycles of treatment with the antibody linvoseltamab had detectable disease on highly sensitive tests. This preliminary success suggests linvoseltamab, a bispecific antibody, could allow patients to avoid bone marrow transplants, which involve intense, high-potency chemotherapy. It also points to the long-term possibility of improving patients’ odds against this disease.

Lead researcher Dickran Kazandjian, M.D., a Sylvester physician and professor in the Myeloma Division at the Miller School, presented updated results today at the American Society of Hematology meeting in Orlando. Dr. Kazandjian conducted the research in collaboration with C. Ola Landgren, M.D., Ph.D., director of Sylvester Myeloma Institute.

“These patients received modern and effective, up-front treatment that eliminated 90% of their tumor,” said Dr. Kazandjian. “Usually, patients like these would receive high-dose chemotherapy and transplant. Instead, we give them a treatment with the drug linvoseltamab.”

Sylvester Comprehensive Cancer Center researchers are investigating ways to eradicate residual traces of multiple myeloma.

Stanford AI Experts Predict What Will Happen in 2026

After years of fast expansion and billion-dollar bets, 2026 may mark the moment artificial intelligence confronts its actual utility. In their predictions for the next year, Stanford faculty across computer science, medicine, law, and economics converge on a striking theme: The era of AI evangelism is giving way to an era of AI evaluation. Whether it’s standardized benchmarks for legal reasoning, real-time dashboards tracking labor displacement, or clinical frameworks for vetting the flood of medical AI startups, the coming year demands rigor over hype. The question is no longer “Can AI do this?” but “How well, at what cost, and for whom?”

Learn more about what Stanford HAI faculty expect in the new year.

Increasing Postpartum Use of GLP-1 Receptor Agonists

Postpartum prescription of GLP-1RAs in Denmark increased between 2018 and 2024, with semaglutide accounting for most prescriptions since 2023.

Most users had overweight or obesity, and only 23% had a diabetes diagnosis, suggesting weight reduction as the main reason for use.

This study uses data from the Danish Medical Birth Register to examine postpartum use of glucagon-like peptide 1 receptor agonists.

Control of aging-associated neurodegeneration via hypothalamic extracellular vesicles containing parathymosin

Jung, Yu, Choi et al. reveal a critical neuroprotective role of PTMS, while loss of this protein causes severe neurodegeneration. Hypothalamic neural stem cell-derived extracellular vesicles carrying PTMS protect neurons by preventing DNA damage and offer therapeutic benefits against aging-related neurodegenerative and Alzheimer’s-like conditions in animal models.

Prediabetes rates soar among children with overweight as maternal weight rises

The prevalence of prediabetes has increased significantly in recent years among Finnish children living with overweight or obesity, a recent study by Tampere University and the University of Eastern Finland shows. In the early 2000s, 11% of those studied had prediabetes, whereas 20 years later, the prevalence of prediabetes was 50%. The prevalence of obesity remained unchanged during the study period, but prediabetes became more common among children, which could, in part, be due to a simultaneous increase in maternal overweight.

The study, published in the International Journal of Obesity, included 602 children aged 6 to 16 who had been assessed for overweight or obesity in primary health care or specialized health care in Tampere between 2002 and 2020. The study also included a control group of 483 children aged 7–16, which had been drawn from the Physical Activity and Nutrition in Children (PANIC) study, underway at the University of Eastern Finland.

According to the study, 34% of children who had been assessed for overweight or obesity had prediabetes, and 1% had type 2 diabetes. In the control group, 7% had prediabetes, while type 2 diabetes was not observed. Prediabetes was more common in older children and those in more advanced stages of puberty. Its prevalence was also associated with fatty liver disease and acanthosis nigricans, a skin condition often linked to overweight and disturbances in glucose metabolism.

/* */